St. Jude Announces Buyback - Analyst Blog
December 16 2011 - 4:00AM
Zacks
Medical technology giant
St. Jude (STJ) recently announced that its Board
has authorized a new share buyback program, allowing it to
repurchase up to $300 million of its common stock. The buyback will
be executed at prices and time determined by management through
open market transactions, privately negotiated transactions, or
other means.
The Minnesota-based company stated
that shares acquired in the repurchase program will be used for
general corporate purposes. The company had roughly 320 million
shares outstanding as of December 12.
Separately, St. Jude has kept its
dividend for the fourth quarter at 21 cents a share (84 cents
annualized), consistent with the dividend paid in the first three
quarters of 2011. The company commenced paying quarterly cash
dividend in February 2011.
St. Jude remains confident that it
has reached a level where it can return value to investors in the
form of dividends while continuing to invest in growth programs
along with share repurchases and acquisitions. During third-quarter
2011, the company completed the $500 million repurchase program
announced in August 2011.
St. Jude’s revenues and earnings
for the third quarter beat the Zacks Consensus Estimates. Profit
surged roughly 9% year over year as higher revenues more than
offset hefty special charges. Revenue jumped 11.5%, led by healthy
double-digit growth across the company’s Cardiovascular and Atrial
Fibrillation franchises, aided by the AGA Medical acquisition.
St. Jude is consistently producing
revenue growth and positive earnings surprise over the past several
quarters. We are impressed by its solid fundamentals, healthy
growth trajectory, strong product mix, robust pipeline and cost
management initiatives.
A spate of new growth drivers
(including new products and emerging markets) are expected to offer
opportunities for accelerated sales growth over the next few
years. However, we remain wary about competition-driven
pricing pressure in a soft CRM market.
A still choppy CRM space
overhangs on St. Jude and its peers
Medtronic (MDT) and Boston
Scientific (BSX). Our long-term Neutral recommendation on
St. Jude is in tandem with a short-term Zacks #3 Rank (Hold).
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jul 2023 to Jul 2024